QDEL vs CTKB
Side-by-side comparison of price performance, valuation, growth, profitability, analyst targets and technical trend.
QDEL · QuidelOrtho$8.32 ▼ 6.73%
CTKB · Cytek Biosciences$6.12 ▼ 3.16%
One year, rebased to 100
Each line starts at 100 so growth is directly comparable
- QDEL -68.7%
- CTKB +4.8%
Head to head
| Metric | QDEL | CTKB |
|---|---|---|
| Price | $8.32 | $6.12 |
| Change today | ▼ 6.73% | ▼ 3.16% |
| Market cap | $570.86M | $800.40M |
| Return, 3 months | -42.6% | +37.8% |
| Return, year to date | -70.9% | +21.2% |
| Return, 1 year | -65.8% | +4.1% |
| P/E (TTM) | – | – |
| P/B | 0.3 | 2.5 |
| P/E percentile vs own 5y | 31st | 70th |
| Dividend yield | – | – |
| Revenue growth (YoY, latest qtr) | -11.6% | +1.8% |
| Net profit growth (YoY) | +92.7% | -11.3% |
| Gross margin | 44.2% | 54.7% |
| Operating margin | -2.6% | -21.1% |
| Net margin | -14.2% | -39.1% |
| Return on equity | -19.3% | -23.2% |
| Analyst target vs. price | +44.2% | +18.5% |
| Analyst buy share | 50% | 100% |
| RSI (14) | 29 | 57 |
| 30-day volatility | 99.7% | 58.9% |
| Max drawdown, 1 year | -76.5% | -42.9% |
| Trend read | Strong downtrend | Strong uptrend |
| Analyst consensus | Hold | Buy |
Green cells mark the best value in each row where "better" is clear-cut (lower P/E, higher margin). That is a reading of the numbers, not a recommendation. Financials are in each company's reporting currency.
What the numbers say
- CTKB is the largest of the group by market value.
- CTKB has returned the most over the past year.
- CTKB is growing revenue fastest.
- QDEL keeps the most profit per dollar of sales.
- CTKB has been the calmest stock over the last 30 days.